Deborah R Kim1, Eileen Wang2, Brendan McGeehan3, Jessica Snell3, Grace Ewing3, Claudia Iannelli3, John P O'Reardon3, Mary D Sammel4, C Neill Epperson3. 1. Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, 3535 Market Street, 3rd Floor, Philadelphia, PA, 19014, United States. Electronic address: drkim@pennmedicine.upenn.edu. 2. Department of Obstetrics and Gynecology, Perelman School of Medicine at the University of Pennsylvania, 3535 Market Street, 3rd Floor, Philadelphia, PA, 19014, United States. 3. Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, 3535 Market Street, 3rd Floor, Philadelphia, PA, 19014, United States. 4. Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine at the University of Pennsylvania, 3535 Market Street, 3rd Floor, Philadelphia, PA, 19014, United States.
Abstract
BACKGROUND: Major depressive disorder (MDD) affects 10% of pregnancies. Because transcranial magnetic stimulation (TMS) is a nonmedication option, psychiatric patients who do not tolerate or prefer to avoid antidepressants are good candidates for TMS. METHOD: In a randomized controlled trial of twenty-two women with MDD in the second or third trimester of pregnancy, subjects were randomized to active TMS (n=11) or sham TMS (n=11). This study took place at a single academic center. Subjects received 20 sessions of TMS to the right dorsolateral prefrontal cortex at 1 Hz as a single train of 900 pulses per session at 100% motor threshold. Estradiol and progesterone and were measured before session 1 and after session 20. RESULTS: Results demonstrated significantly decreased Hamilton Depression Rating Scale (HDRS-17) scores for the active compared to the sham group (p=0.003). Response rates were 81.82% for the active and 45.45% for the sham coil (p=0.088). Remission rates were 27.27% for the active 18.18% for the sham coil (p=0.613). Late preterm birth (PTB) occurred in three women receiving active TMS. All other maternal and delivery outcomes were normal. CONCLUSIONS: Right-sided, low frequency TMS was effective in reducing depressive symptoms in this sample of pregnant women. There may be a possibility that TMS is associated with late PTB although a larger sample size would be needed for adequate power to detect a true difference between groups. This study demonstrated that TMS is low risk during pregnancy although larger trials would provide more information about the efficacy and safety of TMS in this population. This trial shows that an RCT of a biologic intervention in pregnant women with psychiatric illness can be conducted.
RCT Entities:
BACKGROUND:Major depressive disorder (MDD) affects 10% of pregnancies. Because transcranial magnetic stimulation (TMS) is a nonmedication option, psychiatricpatients who do not tolerate or prefer to avoid antidepressants are good candidates for TMS. METHOD: In a randomized controlled trial of twenty-two women with MDD in the second or third trimester of pregnancy, subjects were randomized to active TMS (n=11) or sham TMS (n=11). This study took place at a single academic center. Subjects received 20 sessions of TMS to the right dorsolateral prefrontal cortex at 1 Hz as a single train of 900 pulses per session at 100% motor threshold. Estradiol and progesterone and were measured before session 1 and after session 20. RESULTS: Results demonstrated significantly decreased Hamilton Depression Rating Scale (HDRS-17) scores for the active compared to the sham group (p=0.003). Response rates were 81.82% for the active and 45.45% for the sham coil (p=0.088). Remission rates were 27.27% for the active 18.18% for the sham coil (p=0.613). Late preterm birth (PTB) occurred in three women receiving active TMS. All other maternal and delivery outcomes were normal. CONCLUSIONS: Right-sided, low frequency TMS was effective in reducing depressive symptoms in this sample of pregnant women. There may be a possibility that TMS is associated with late PTB although a larger sample size would be needed for adequate power to detect a true difference between groups. This study demonstrated that TMS is low risk during pregnancy although larger trials would provide more information about the efficacy and safety of TMS in this population. This trial shows that an RCT of a biologic intervention in pregnant women with psychiatric illness can be conducted.
Authors: M P Szuba; J P O'Reardon; A S Rai; J Snyder-Kastenberg; J D Amsterdam; D R Gettes; E Wassermann; D L Evans Journal: Biol Psychiatry Date: 2001-07-01 Impact factor: 13.382
Authors: Jeffrey J Borckardt; John Walker; R Kyle Branham; Sofia Rydin-Gray; Caroline Hunter; Heather Beeson; Scott T Reeves; Alok Madan; Harold Sackeim; Mark S George Journal: Brain Stimul Date: 2008-01 Impact factor: 8.955
Authors: M S George; E M Wassermann; W A Williams; A Callahan; T A Ketter; P Basser; M Hallett; R M Post Journal: Neuroreport Date: 1995-10-02 Impact factor: 1.837
Authors: Chris Baeken; Anna-Katharine Brem; Martijn Arns; Andre R Brunoni; Igor Filipčić; Ana Ganho-Ávila; Berthold Langguth; Frank Padberg; Emmanuel Poulet; Fady Rachid; Alexander T Sack; Marie-Anne Vanderhasselt; Djamila Bennabi Journal: Curr Opin Psychiatry Date: 2019-09 Impact factor: 4.741